Others: Tissue hypoperfusion (measures with lactate level or scoring systems) Harms: Any treatments harms Q3 Is Adults and children (not Timing: early (< late (< 72h, Primary outcome response to neonates) 24h) < 7 days, < 1. Resolution (or treatment and critical illness with 14 days) improvement) of acute dependent on: CIRCI (as defined by Daily dose: 300 >300 HC of manifestations ≤ (a) time, original studies’ mg HC (equivalent) CIRCI [shock; (b) dose, authors) (equivalent) respiratory failure; (c) duration, MODS; etc.] OR (d) tapering. Septic shock Duration: versus short (<72 clinical cure as defined long ( 72 hours) by primary author of ≥ Q3b. Does ARDS days; 14 studies ≥7 ≥ secondary days; 21 days) ≥ prevention Trauma 2. Mortality hospital or improve Multiple trauma Tapering: fast (≤ No tapering 28 or 90 days] overall Head trauma 4 days) OR slow response to (>4 days) Secondary outcomes: treatment? No Effective Implementation response of secondary of [cytokines, CRP, etc.] prevention secondary prevention Duration of: treatment, ICU stay, hospital stay Medium-long-term outcome:
Others: Tissue hypoperfusion (measures with lactate level or scoring systems) Harms: Any treatments harms Q3 Is response to treatment dependent on: (a) time, (b) dose, (c) duration, (d) tapering. Q3b. Does secondary prevention improve overall response to treatment? Adults and children (not neonates) and critical illness with CIRCI (as defined by original studies’ authors) Septic shock ARDS Trauma Multiple trauma Head trauma Timing: early (< 24h) Daily dose: ≤ 300 mg HC (equivalent) Duration: versus long ( ≥ 72 ≥7 days; ≥ 14 days; ≥ 21 days) Tapering: fast (≤ 4 days) OR slow (>4 days) Implementation of secondary prevention late (< 72h, < 7 days, < 14 days) >300 HC (equivalent) short (<72 hours) No tapering No of secondary prevention Primary outcome 1. Resolution (or improvement) of acute manifestations of CIRCI [shock; respiratory failure; MODS; etc.] OR clinical cure as defined by primary author of studies 2. Mortality hospital or 28 or 90 days] Secondary outcomes: Effective response [cytokines, CRP, etc.] Duration of: treatment, ICU stay, hospital stay Medium-long-term outcome:
CCM_45_12_2017_09_14_ANNANE_CCMED-D-17-01644_SDC1.docx